| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 54.86 | 0.30 (+0.55%) | 33.03 - 55.86 | 1.3 million (Above Avg) |
Market data as of 4:02PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 54.80 |
|---|---|
| Previous Close | 54.56 |
| Day's Range | 54.36 - 54.88 |
| Market Cap | 145.2B |
| Avg Volume (10 Day) | 1.2M |
| Price/Earnings (Trailing 12 Mo.) | 30.3x |
| Earnings Per Share (Trailing 12 Mo.) | 1.81 |
| Dividend Yield | 1.69 (3.08%) |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Pass |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Pass |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
PR Newswire - Tuesday 05/21/2013 8:15 AM ET
Sanofi Relies on Axway to Future-Proof their Infrastructure and Reduce Operational Costs through Global Consolidation
Business Wire - Tuesday 05/21/2013 2:00 AM ET
Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
PR Newswire - Friday 05/17/2013 8:00 AM ET
Football Legend Jerome Bettis & Sanofi US Tackle Anaphylaxis During National Asthma and Allergy Awareness Month
PR Newswire - Thursday 05/16/2013 8:00 AM ET
Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
PR Newswire - Wednesday 05/15/2013 1:00 AM ET
PatientsLikeMe and CISCRP Team up with Sanofi to Spotlight Medical Heroes and Clinical Trial Participation
Business Wire - Monday 05/13/2013 10:00 AM ET
New Gold Bond® No Mess Powder Spray Introduced by Sanofi's Chattem
PR Newswire - Monday 05/06/2013 3:13 PM ET
Sanofi US and Actress Elizabeth Perkins Premiere Documentary -- Diabetes Co-Stars Presents "Strength in Numbers"
PR Newswire - Monday 05/06/2013 8:00 AM ET
| SNY | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -27.85% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | 3.30% | |
| Price/Sales | 4.34 |
| Company | Last | Change |
|---|---|---|
| GlaxoSmithKline PLC | 52.97 | +0.46% |
| Merck & Co Inc | 47.16 | -0.36% |
| Novartis AG | 74.36 | +0.73% |
| Pfizer Inc | 29.04 | -0.24% |
| Bristol-Myers Squibb Co | 47.40 | +0.85% |
Data is delayed by at least 15 min.